Identifying patients at high risk for <font color="blue">neutropenic_1</font> <font color="blue">complications_1</font> during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin : the <font color="blue">development_1</font> <font color="blue">of_1</font> <font color="blue">a_1</font> <font color="blue">prediction_1</font> <font color="blue">model_1</font> <font color="blue">._1</font> 
<br>
<br> OBJECTIVE <font color="blue">To_1</font> <font color="blue">develop_1</font> <font color="blue">a_1</font> <font color="blue">cycle_1</font> <font color="blue">-_1</font> <font color="blue">based_1</font> <font color="blue">risk_1</font> <font color="blue">prediction_1</font> <font color="blue">model_1</font> <font color="blue">for_1</font> <font color="blue">neutropenic_2</font> <font color="blue">complications_2</font> <font color="blue">(_2</font> <font color="blue">NC_2</font> <font color="blue">)_2</font> <font color="blue">during_1</font> <font color="blue">chemotherapy_1</font> <font color="blue">with_1</font> <font color="blue">doxorubicin_1</font> <font color="blue">(_1</font> <font color="blue">DOX_1</font> <font color="blue">)_1</font> <font color="blue">or_1</font> <font color="blue">a_1</font> <font color="blue">pegylated_1</font> <font color="blue">liposomal_1</font> <font color="blue">formulation_1</font> <font color="blue">(_1</font> <font color="blue">PLD_1</font> <font color="blue">)_1</font> <font color="blue">for_1</font> <font color="blue">patients_1</font> <font color="blue">with_1</font> <font color="blue">metastatic_1</font> <font color="blue">breast_1</font> <font color="blue">cancer_1</font> <font color="blue">(_1</font> <font color="blue">MBC_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> <font color="blue">
<br>_1</font> METHODS Data analyzed was from a phase III , randomized clinical trial of DOX ( 60 mg / m(2 ) every 3 weeks ) or PLD ( 50 mg / m(2 ) every 4 weeks ) for the first line therapy for MBC ( n = 509 ) ( O'Brien et al , Ann Oncol . 2004;15:440 - 449 ) . <font color="blue">NC_1</font> <font color="blue">were_1</font> <font color="blue">defined_1</font> <font color="blue">as_1</font> <font color="blue">an_1</font> <font color="blue">absolute_2</font> <font color="blue">neutrophil_2</font> <font color="blue">count_2</font> <font color="blue"><_1</font> <font color="blue">or_1</font> <font color="blue">=_1</font> <font color="blue">1.5_1</font> <font color="blue">x_1</font> <font color="blue">10(9_1</font> <font color="blue">)_1</font> <font color="blue">cells_1</font> <font color="blue">/_1</font> <font color="blue">L_1</font> <font color="blue">(_1</font> <font color="blue">ie_1</font> <font color="blue">,_1</font> <font color="blue">>_1</font> <font color="blue">or_1</font> <font color="blue">=_1</font> <font color="blue">grade_1</font> <font color="blue">II_1</font> <font color="blue">)_1</font> <font color="blue">before_1</font> <font color="blue">the_1</font> <font color="blue">next_1</font> <font color="blue">cycle_1</font> <font color="blue">,_1</font> <font color="blue">febrile_1</font> <font color="blue">neutropenia_1</font> <font color="blue">or_1</font> <font color="blue">neutropenia_1</font> <font color="blue">with_1</font> <font color="blue">a_1</font> <font color="blue">documented_1</font> <font color="blue">infection_1</font> <font color="blue">._1</font> <font color="blue">Patient_1</font> <font color="blue">and_1</font> <font color="blue">hematologic_1</font> <font color="blue">factors_1</font> potentially associated with NC were evaluated . Factors with a P value of < or = 0.25 within a cycle were included in a generalized estimating equations regression model . Using backward elimination , we derived <font color="blue">a_1</font> <font color="blue">risk_1</font> <font color="blue">scoring_1</font> <font color="blue">algorithm_1</font> ( range 0 - 63 ) from the final reduced model . 
<br> RESULTS Risk factors retained in the model included <font color="blue">poor_1</font> <font color="blue">performance_1</font> <font color="blue">status_1</font> <font color="blue">,_1</font> <font color="blue">absolute_1</font> <font color="blue">neutrophil_1</font> <font color="blue">count_1</font> <font color="blue"><_1</font> <font color="blue">or_1</font> <font color="blue">=_1</font> <font color="blue">2.0_1</font> <font color="blue">x_1</font> <font color="blue">10(9_1</font> <font color="blue">)_1</font> <font color="blue">cells_1</font> <font color="blue">/_1</font> <font color="blue">L_1</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">previous_1</font> <font color="blue">cycle_1</font> <font color="blue">,_1</font> <font color="blue">the_1</font> <font color="blue">first_1</font> <font color="blue">cycle_1</font> <font color="blue">of_1</font> <font color="blue">chemotherapy_1</font> <font color="blue">,_1</font> <font color="blue">DOX_1</font> <font color="blue">versus_1</font> <font color="blue">PLD_1</font> <font color="blue">and_1</font> <font color="blue">advanced_1</font> <font color="blue">age_1</font> <font color="blue">._1</font> <font color="blue">A_1</font> <font color="blue">precycle_1</font> <font color="blue">risk_1</font> <font color="blue">score_1</font> <font color="blue">from_1</font> <font color="blue">>_1</font> <font color="blue">or_1</font> <font color="blue">=_1</font> <font color="blue">25_1</font> <font color="blue">to_1</font> <font color="blue"><_1</font> <font color="blue">40_1</font> <font color="blue">for_1</font> <font color="blue">a_1</font> <font color="blue">given_1</font> <font color="blue">patient_1</font> <font color="blue">was_1</font> <font color="blue">identified_1</font> <font color="blue">as_1</font> <font color="blue">being_1</font> <font color="blue">the_1</font> <font color="blue">optimal_1</font> <font color="blue">threshold_1</font> <font color="blue">for_1</font> <font color="blue">sensitivity_1</font> <font color="blue">(_1</font> <font color="blue">58.0%_1</font> <font color="blue">)_1</font> <font color="blue">and_1</font> <font color="blue">specificity_1</font> <font color="blue">(_1</font> <font color="blue">78.7%_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> <font color="blue">Patients_1</font> <font color="blue">with_1</font> <font color="blue">a_1</font> <font color="blue">score_1</font> <font color="blue">at_1</font> <font color="blue">or_1</font> <font color="blue">beyond_1</font> <font color="blue">this_1</font> <font color="blue">threshold_1</font> <font color="blue">would_1</font> <font color="blue">be_1</font> <font color="blue">considered_1</font> <font color="blue">at_1</font> <font color="blue">high_1</font> <font color="blue">risk_1</font> <font color="blue">for_1</font> <font color="blue">developing_1</font> <font color="blue">NC_1</font> <font color="blue">in_1</font> <font color="blue">later_1</font> <font color="blue">cycles_1</font> <font color="blue">._1</font> 
<br> CONCLUSION The use of this model may enhance patient care by targeting preventative therapies ( eg , granulocyte colony stimulating factor or PLD ) to those MBC patients most likely to experience NC during anthracycline - based chemotherapy .